<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102591">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02013960</url>
  </required_header>
  <id_info>
    <org_study_id>0099-13-RMB CTIL</org_study_id>
    <nct_id>NCT02013960</nct_id>
  </id_info>
  <brief_title>Misoprostol vs. Sublingual Misoprostol and Laminaria For Second Trimester Termination of Pregnancy</brief_title>
  <official_title>Comparison Between Sublingual Misoprostol vs. Sublingual Misoprostol and Laminaria For Second Trimester Termination of Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Comparison between the duration of  time from the beginning  of cervical preparation
           until abortion, between sublingual  misoprostol and the combination of sublingual
           misoprostol with  laminaria for second trimester medical termination of pregnancy
           (TOP).

        2. Comparison between the adverse event rate following Sublingual  misoprostol only vs.
           Sublingual misoprostol and laminaria given for pregnancy termination.

        3. Comparison between the levels of satisfaction rate of women who underwent pregnancy
           termination with sublingual misoprostol vs. sublingual misoprostol with laminaria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized control trial; 50 women undergoing pregnancy termination in the
      second trimester (14-28 weeks)in each group.

      Following receiving an ethical approval by the local institutional review board (IRB),
      committee, consecutively all women in between 14 weeks to 28 weeks; that have a reason for
      termination of pregnancy like:  intrauterine fetal death or medical or genetic indications
      for termination of pregnancy or socioeconomic termination of pregnancy will  be offered to
      take part in the study.  If eligible according to the inclusion and exclusion criteria,
      women will be asked to sign a consent form.

      All participants will undergo blood exams (CBC, Prothrombin time, Partial thromboplastin
      time , and BLOOD TYPING) and ultrasound exam for Confirmation of diagnosis as routinely
      indicated for missed abortion at our department
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Duration of time until pregnancy termination</measure>
    <time_frame>Average time 12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>From the time of receiving the treatment until complete abortion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Other Abortion</condition>
  <arm_group>
    <arm_group_label>Laminaria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cytotec and laminaria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytotec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cytotec only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytotec</intervention_name>
    <description>Cytotec medication compared with cytotec and laminaria</description>
    <arm_group_label>Laminaria</arm_group_label>
    <arm_group_label>Cytotec</arm_group_label>
    <other_name>Misorpristol vs. Misopristol and laimnria</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Second trimester pregnancy No evidence of chorioamnionitis

        Exclusion Criteria:

        Allergy to misoprostol. Evidence for infection. Asthma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nibal Awad, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Health Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 11, 2013</lastchanged_date>
  <firstreceived_date>September 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Awad Nibal MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
